The learned intermediary doctrine lets a prescription drug or medical device manufacturer satisfy its legal duty to warn by giving complete risk information to the prescribing physician rather than directly to the patient. The reasoning is practical: because these products require a doctor’s authorization, the prescriber is treated as the informed gatekeeper who weighs the risks for each individual patient. Nearly every state recognizes some version of the defense, which is why it is often the first argument a drug company raises when a patient sues over an undisclosed side effect.
How the Doctrine Works
Ordinary products liability law tells manufacturers to warn the end user about known dangers. Prescription drugs and medical devices sit outside that default. Patients cannot buy them off the shelf, and a licensed prescriber has to authorize them. Courts have long held that this gatekeeper structure lets a manufacturer discharge its warning duty by passing adequate risk information to the prescribing physician.1The Climate Change and Public Health Law Site. Liability of Commercial Seller or Distributor for Harm Caused by Defective Prescription Drugs and Medical Devices
So when a patient sues claiming they were never told about a drug’s side effects, the company’s first move is usually to show the doctor was warned. If that showing holds, the manufacturer generally escapes liability for the injury even though the patient personally never heard the warning. The responsibility shifts to the physician, who was supposed to relay what mattered as part of the prescribing conversation.
That is not a free pass. The warning actually has to be adequate, and several exceptions can take the defense away entirely.
What Counts as an Adequate Warning
The defense only protects manufacturers that clear a high bar. A warning qualifies as adequate when it clearly communicates all known risks, side effects, and dangerous drug interactions to the prescribing physician. Vague or incomplete disclosures do not hold up.
The duty is also ongoing. When post-market surveillance reveals a new risk or the medical literature identifies a previously unknown interaction, the company has to update its warnings promptly. Sitting on adverse event data or failing to revise labeling after learning of a new danger can destroy the defense.
Courts look at whether the warning was specific enough for a trained physician to appreciate the risk, whether it was prominently placed rather than buried, and whether it addressed the particular injury the plaintiff suffered. A warning about nausea does nothing to shield a manufacturer from liability for cardiac arrest if cardiovascular risks were known but undisclosed.
Where the Rule Comes From
Comment k to Section 402A of the Restatement (Second) of Torts treated prescription drugs as “unavoidably unsafe products.” Under Comment k, such a product is “not defective, nor is it unreasonably dangerous” when it is properly prepared and “accompanied by proper directions and warning.” That comment became the doctrinal anchor for the defense.
The Restatement (Third) of Torts: Products Liability, Section 6(d), updated the framework. A prescription drug or device is not reasonably safe if the manufacturer fails to provide reasonable warnings about foreseeable risks to “prescribing and other health-care providers who are in a position to reduce the risks of harm.” Section 6(d)(2) adds that warnings must go directly to the patient when the manufacturer knows or has reason to know healthcare providers will not be in a position to reduce the risk, which effectively codifies the mass immunization exception.1The Climate Change and Public Health Law Site. Liability of Commercial Seller or Distributor for Harm Caused by Defective Prescription Drugs and Medical Devices
Proving a Failure-to-Warn Case Anyway
Even when the warning falls short, the plaintiff does not win automatically. The missing piece is causation, and this is where failure-to-warn cases collapse more often than plaintiffs expect.
Because the warning runs through the doctor, there is an extra link in the causation chain. The plaintiff typically has to show that an adequate warning would have changed the doctor’s prescribing decision, or that the doctor would have passed the risk along to the patient, who would then have declined the treatment. Courts vary on the exact standard. Some require evidence the physician would have altered the prescription. Others let the plaintiff show the doctor would have relayed the warning and a reasonable patient in the plaintiff’s position would have refused the drug.
Many states ease that burden with a heeding presumption. Once the plaintiff proves the warning was inadequate, the court presumes the plaintiff would have followed an adequate warning if one had been given. The manufacturer then has to prove a proper warning would have made no difference, for example by showing no alternative treatment existed and the patient would have taken the drug regardless.
When the Doctrine Does Not Apply
The defense rests on the assumption that a physician stands between the manufacturer and the patient, making an individualized medical judgment. When that assumption breaks down, so does the defense.
Direct-to-Consumer Advertising
In Perez v. Wyeth Laboratories, the New Jersey Supreme Court held that when a manufacturer markets a drug directly to consumers, it creates a direct relationship that triggers a corresponding duty to warn patients, not just their doctors. The court concluded the doctrine “simply drops out of the calculus” when a manufacturer bypasses the physician to speak directly to patients through advertising.2The Climate Change and Public Health Law Site. Perez v Wyeth Laboratories Inc
New Jersey stands largely alone on this. Most courts that have considered the issue have declined to create a direct-to-consumer advertising exception, reasoning that the physician still makes the final prescribing decision even when a patient walks in asking for a drug by name. Federal regulations under 21 CFR 202.1 already require prescription drug advertisements to present a fair balance between benefit claims and risk information,3eCFR. 21 CFR 202.1 – Prescription Drug Advertisements and some courts treat that regulatory scheme as sufficient consumer protection without expanding tort liability.
Mass Immunization Programs
Vaccines given at mass clinics without individual physician consultations fall outside the doctrine. In Davis v. Wyeth Laboratories, a case involving the Sabin polio vaccine, the Ninth Circuit held that when a drug is “dispensed to all comers at mass clinics without an individualized balancing by a physician of the risks involved,” the manufacturer cannot shift the warning duty to a doctor who never evaluated the patient. The warning has to reach recipients directly, “either by giving warning itself or by obligating the purchaser to give warning.”4The Climate Change and Public Health Law Site. Davis v Wyeth Laboratories Inc
Congress built on this through the National Childhood Vaccine Injury Act of 1986, which requires vaccine information materials for distribution to recipients of listed vaccines.5Congress.gov. National Childhood Vaccine Injury Act of 1986 The Act shields manufacturers from liability based solely on failure to provide direct warnings about unavoidable side effects, but still allows liability for fraudulent or intentional withholding of safety information.
Device Representatives in the Operating Room
A less obvious exception comes up when a device manufacturer’s sales representative is in the operating room and moves from technical advisor to active participant. If the representative recommends using a device outside its approved specifications, directs the surgeon’s technique, or adjusts settings inconsistent with the manufacturer’s own manual, courts have found the manufacturer forfeited the defense. A company cannot claim the doctor was the intermediary when its own employee was in the room overriding the doctor’s judgment.
Brand-Name vs. Generic Drugs: The Preemption Divide
Federal preemption creates a stark split between brand-name and generic drug manufacturers, and anyone injured by a prescription drug needs to know which category their medication falls into, because it can decide whether a lawsuit is even possible.
Brand-name manufacturers can generally be sued under state failure-to-warn law. In Wyeth v. Levine (2009), the Supreme Court held that FDA approval of a drug’s labeling does not preempt state tort claims. A manufacturer “bears responsibility for the content of its label at all times” and can unilaterally strengthen warnings through the FDA’s “changes being effected” regulation without waiting for prior agency approval.6Library of Congress. Wyeth v Levine, 555 US 555 (2009) FDA approval is not a shield for a brand-name company that knows its warning is inadequate.
Generic manufacturers sit in a very different place. In PLIVA, Inc. v. Mensing (2011), the Supreme Court held that because federal regulations require generic drugs to carry the same labeling as their brand-name equivalents, it is “impossible” for generic manufacturers to comply with both a state-law duty to strengthen warnings and the federal duty to keep labels identical. State failure-to-warn claims against generic manufacturers are therefore preempted.7Justia US Supreme Court. PLIVA Inc v Mensing, 564 US 604 (2011) Two years later, in Mutual Pharmaceutical Co. v. Bartlett, the Court extended that reasoning to state-law design-defect claims against generic manufacturers.8Justia US Supreme Court. Mutual Pharmaceutical Co v Bartlett, 570 US 472 (2013)
The practical impact is enormous. Generic drugs account for roughly 90% of prescriptions filled in the United States. A patient injured by a generic drug’s inadequately warned side effect may have no viable failure-to-warn claim against the generic manufacturer, even when the identical claim would succeed against the brand-name company. Some plaintiffs have tried to sue the brand-name manufacturer whose label the generic copied, but courts are split on whether that theory holds up.
Pressure Points on the Modern Doctrine
Not every state is on board. West Virginia’s Supreme Court declined to adopt the doctrine in 2007, concluding that its assumptions no longer reflect how medicine is actually practiced. West Virginia remains an outlier, but its reasoning points at pressure that exists everywhere.
Prescribing authority has expanded to nurse practitioners and physician assistants, and in many settings patients see one of them rather than a physician. Courts have not uniformly addressed whether the defense applies with the same force when the prescriber is not a doctor.
Pharmacists are a separate question. Most courts hold they are not learned intermediaries with a general duty to warn patients about drug side effects, since the prescribing decision belongs to the physician or other authorized prescriber. A minority of courts recognize limited exceptions for situations like clearly excessive dosages or known dangerous interactions a pharmacist would spot while filling a prescription.
The broader criticism goes to the model itself. It assumes physicians have time and opportunity to explain drug risks during each patient encounter and that patients meaningfully participate in prescribing decisions. Whether that matches the reality of short-appointment, high-volume medical practice is an open question that courts and legislatures will keep working through.